"Proprotein Convertase 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proprotein convertase that is essential for CHOLESTEROL homeostasis. It binds to and is required for the lysosomal degradation of the LDL RECEPTOR (LDLR); the VLDL receptor, and the APOLIPOPROTEIN E RECEPTOR. It also regulates neuronal APOPTOSIS.
| Descriptor ID |
D000071449
|
| MeSH Number(s) |
D08.811.277.656.300.760.718 D08.811.277.656.837.688 D08.811.277.656.959.350.718
|
| Concept/Terms |
Proprotein Convertase 9- Proprotein Convertase 9
- Convertase 9, Proprotein
- Neural Apoptosis-Regulated Convertase 1
- Neural Apoptosis Regulated Convertase 1
- NARC-1 Protein
- NARC 1 Protein
- Proprotein Convertase, Subtilisin-Kexin Type 9
- Proprotein Convertase, Subtilisin Kexin Type 9
|
Below are MeSH descriptors whose meaning is more general than "Proprotein Convertase 9".
Below are MeSH descriptors whose meaning is more specific than "Proprotein Convertase 9".
This graph shows the total number of publications written about "Proprotein Convertase 9" by people in this website by year, and whether "Proprotein Convertase 9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 2 | 2 | 4 |
| 2021 | 1 | 0 | 1 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proprotein Convertase 9" by people in Profiles.
-
Detrimental effects of PCSK9 loss-of-function in the pediatric host response to sepsis are mediated through independent influence on Angiopoietin-1. Crit Care. 2023 06 26; 27(1):250.
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
-
Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug; 16(4):538-543.
-
Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial. Sci Transl Med. 2021 04 21; 13(590).
-
Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock. Crit Care Med. 2020 10; 48(10):1513-1520.
-
Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2747-2755.
-
Regulatory T Cells License Macrophage Pro-Resolving Functions During Atherosclerosis Regression. Circ Res. 2020 07 17; 127(3):335-353.
-
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. BioDrugs. 2020 Feb; 34(1):1-9.
-
A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes. Clin Pharmacol Ther. 2020 06; 107(6):1383-1393.
-
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). Am J Cardiol. 2019 12 15; 124(12):1876-1880.